Literature DB >> 30106070

Time-dependent shotgun proteomics revealed distinct effects of an organoruthenium prodrug and its activation product on colon carcinoma cells.

Samuel M Meier-Menches1, Katja Zappe, Andrea Bileck, Dominique Kreutz, Ammar Tahir, Margit Cichna-Markl, Christopher Gerner.   

Abstract

Activation kinetics of metallo-prodrugs control the types of possible interactions with biomolecules. The intact metallo-prodrug is able to engage with potential targets by purely non-covalent bonding, while the activated metallodrug can form additional coordination bonds. It is hypothesized that the additional coordinative bonding might be favourable with respect to the target selectivity of activated metallodrugs. Thus, a time-dependent shotgun proteomics study was conducted in HCT116 colon carcinoma cells with plecstatins, which are organoruthenium anticancer drug candidates. First, the target selectivity was evaluated in a time-dependent fashion, which accounted for their hydrolysis kinetics. The binding selectivity increased from 50- to 160-fold and the average specificity from 0.72 to 0.86, respectively, from the 2 h to the 4 h target profiling experiment. Target profiling after 19 h did not reveal significant enrichments, possibly due to deactivation of the probe via arene cleavage. Up to 450 interactors were identified in the target profiling experiments. A plecstatin analogue that substituted a hydrogen bond acceptor with a hydrogen bond donor abrogated the target selectivity for plectin in HCT116 whole cell lysates, underlining the necessity of this hydrogen bond acceptor for a strong interaction between plecstatin and plectin. Second, time-dependent response profiling experiments provided evidence that plecstatin-2 induced an integrated stress response (ISR) in HCT116 cell culture. The phosphorylation of eIF2α, a key mediator of the ISR, after 3 h treatment indicated that this perturbation was initiated by the intact plecstatin-2 prodrug, while the effects of plectin-targeting are mediated by activated plecstatin-2.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30106070     DOI: 10.1039/c8mt00152a

Source DB:  PubMed          Journal:  Metallomics        ISSN: 1756-5901            Impact factor:   4.526


  8 in total

Review 1.  Metal-based anticancer agents as immunogenic cell death inducers: the past, present, and future.

Authors:  Sajal Sen; Miae Won; Matthew S Levine; Yuvin Noh; Adam C Sedgwick; Jong Seung Kim; Jonathan L Sessler; Jonathan F Arambula
Journal:  Chem Soc Rev       Date:  2022-02-21       Impact factor: 60.615

2.  Interaction with Ribosomal Proteins Accompanies Stress Induction of the Anticancer Metallodrug BOLD-100/KP1339 in the Endoplasmic Reticulum.

Authors:  Benjamin Neuditschko; Anton A Legin; Dina Baier; Arno Schintlmeister; Siegfried Reipert; Michael Wagner; Bernhard K Keppler; Walter Berger; Samuel M Meier-Menches; Christopher Gerner
Journal:  Angew Chem Int Ed Engl       Date:  2021-02-01       Impact factor: 15.336

3.  Impact of the Metal Center and Leaving Group on the Anticancer Activity of Organometallic Complexes of Pyridine-2-carbothioamide.

Authors:  Jahanzaib Arshad; Kelvin K H Tong; Sanam Movassaghi; Tilo Söhnel; Stephen M F Jamieson; Muhammad Hanif; Christian G Hartinger
Journal:  Molecules       Date:  2021-02-05       Impact factor: 4.411

4.  An Organometallic Gold(I) Bis-N-Heterocyclic Carbene Complex with Multimodal Activity in Ovarian Cancer Cells.

Authors:  Samuel M Meier-Menches; Benjamin Neuditschko; Katja Zappe; Martin Schaier; Marlene C Gerner; Klaus G Schmetterer; Giorgia Del Favero; Riccardo Bonsignore; Margit Cichna-Markl; Gunda Koellensperger; Angela Casini; Christopher Gerner
Journal:  Chemistry       Date:  2020-11-03       Impact factor: 5.236

Review 5.  Plectin in Cancer: From Biomarker to Therapeutic Target.

Authors:  Samantha M Perez; Lindsey T Brinton; Kimberly A Kelly
Journal:  Cells       Date:  2021-08-30       Impact factor: 6.600

6.  A Proteomic Platform Enables to Test for AML Normalization In Vitro.

Authors:  Samuel M Meier-Menches; Benjamin Neuditschko; Lukas Janker; Marlene C Gerner; Klaus G Schmetterer; Albrecht Reichle; Christopher Gerner
Journal:  Front Chem       Date:  2022-02-01       Impact factor: 5.221

7.  Establishment of lactate-metabolism-related signature to predict prognosis and immunotherapy response in patients with colon adenocarcinoma.

Authors:  Zhengrong Zou; Yongjie Chai; Qi Li; Xuan Lin; Qingfang He; Qiusheng Xiong
Journal:  Front Oncol       Date:  2022-09-14       Impact factor: 5.738

Review 8.  Nanomedicines in the treatment of colon cancer: a focus on metallodrugs.

Authors:  Pedro Farinha; Jacinta O Pinho; Mariana Matias; M Manuela Gaspar
Journal:  Drug Deliv Transl Res       Date:  2021-02-22       Impact factor: 4.617

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.